title: A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats.
abstract: BACKGROUND
  A natural p300-specific histone acetyltransferase (HAT) inhibitor, curcumin, may have therapeutic potential for heart failure. However, it is unclear whether curcumin exhibits beneficial additive or synergistic effects on conventional therapy with angiotensin-converting enzyme inhibitors (ACEIs).
  
  
  RESULTS
  Rats were subjected to a sham operation or left coronary artery ligation. One week later, 34 rats with a moderate sized myocardial infarction (MI) were randomly assigned to 4 groups: solvents as control (n = 8), enalapril (an ACEI, 10 mg·kg⁻¹·day⁻¹) alone (n=8), curcumin (50 mg·kg⁻¹·day⁻¹) alone (n = 9) and enalapril plus curcumin (n = 9). Daily oral treatment was repeated and continued for 6 weeks. Echocardiographic data were similar among the 4 groups before treatment. After treatment, left ventricular (LV) fractional shortening (FS) was significantly higher in the enalapril (29.0 ± 1.9%) and curcumin (30.8 ± 1.7%) groups than in the vehicle group (19.7 ± 1.6%). Notably, LVFS further increased in the enalapril/curcumin combination group (34.4 ± 1.8%). Histologically, cardiomyocyte diameter in the non-infarct area was smaller in the enalapril/curcumin combination group than in the enalapril group. Perivascular fibrosis was significantly reduced in the enalapril/curcumin group compared with the curcumin group.
  
  
  CONCLUSIONS
  A natural non-toxic dietary compound, curcumin, combined with an ACEI exerts beneficial effects on post-MI LV systolic function in rats.
authors: Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Japan.
authors: Yoichi
authors: Y
authors: Sunagawa
authors: Tatsuya
authors: T
authors: Morimoto
authors: Hiromichi
authors: H
authors: Wada
authors: Tomohide
authors: T
authors: Takaya
authors: Yasufumi
authors: Y
authors: Katanasaka
authors: Teruhisa
authors: T
authors: Kawamura
authors: Shigeki
authors: S
authors: Yanagi
authors: Akira
authors: A
authors: Marui
authors: Ryuzo
authors: R
authors: Sakata
authors: Akira
authors: A
authors: Shimatsu
authors: Takeshi
authors: T
authors: Kimura
authors: Hideaki
authors: H
authors: Kakeya
authors: Masatoshi
authors: M
authors: Fujita
authors: Koji
authors: K
authors: Hasegawa
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D003474:Curcumin / Q000494:pharmacology*; D050881:E1A-Associated p300 Protein / Q000037:antagonists & inhibitors*; D004562:Electrocardiography; D004656:Enalapril / Q000494:pharmacology*; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013599:Systole; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D004656:Enalapril; D050881:E1A-Associated p300 Protein; C494362:Ep300 protein, rat; D003474:Curcumin